Axial Spondyloarthritis Market, By Type (Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis), By Drug Class (Glucocorticoids, Anti-Rheumatic Drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAID), and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Report Code: PMI517623 | Publish Date: March 2024 | No. of Pages: 176

Axial Spondyloarthritis Market Overview

[PDF] Axial Spondyloarthritis (axSpA) is a type of arthritis which affects joints in axial skeleton such as spine, pelvis, and chest. An individual with axSpA have back pain before 40 age and has more stiffness and pain in young adults which can be severe and debilitating.

Axial Spondyloarthritis Market Drivers and Restrains:

Growing Prevalence of Axial Spondyloarthritis to fuel market growth

Growing prevalence of axial spondyloarthritis (AS) across globe have become major factor in market growth. AS can affect people of all ages. According to the Spondylitis Association of America, an individual can typically develop AS between age of 17 and 45. Mostly an individual develop AS in their age of 20s and 30s and can affect all age people.

For instance, according to (The American Journal of the Medical Sciences), the concept of inflammatory back pain (IBP) and its relationship with axial spondyloarthritis (AxSpA) evolved an instrument developed was further modified and field tested for use in 2009 to 2010 NHANES (National Health and Nutrition Examination Survey) showed the frequency of chronic back pain increased to 19.4% and the prevalence of AxSpA has been defined at 1.0% to 1.4% and AS (ankylosing spondylitis) at 0.52% to 0.55%.

Thus, according to CDC (Centers for Disease Control and Prevention) the growing prevalence of chronic diseases such as diabetes, heart disease, obesity, have given rise in burden of arthritis in United States and estimated that there will be 78 million adults with arthritis by 2040 in America.

Axial Spondyloarthritis Market Dynamics

Restrains:

However, severe adverse effects of certain drugs has hampered the demand for Axial Spondyloarthritis Market growth.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Axial Spondyloarthritis Market Segmentation

Axial Spondyloarthritis Market Segmentation:

Axial Spondyloarthritis Market is segmented based on Type, Drug Class and Region.

Type Insight

On the basis of Type, Axial Spondyloarthritis Market is segmented into Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis.

Drug Class Insights

On the basis of Drug Class, Axial Spondyloarthritis Market is segmented into Glucocorticoids, Anti-Rheumatic Drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAID), and Others.

Axial Spondyloarthritis Market Regional Insights:

On region the Axial Spondyloarthritis Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America market is estimated to witness a significantly high revenue share over the forecast period due to rising prevalence of axial spondyloarthritis, huge investment in research & development activities, robust healthcare infrastructure, continuous technological development and increased awareness among patient about disease.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2022

Forecast period

2022 – 2032

Market representation

Revenue in USD Billion & CAGR from 2022 to 2032

Market Segmentation

By Type - Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis

By Drug Class - Glucocorticoids, Anti-Rheumatic Drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAID), and Others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032.

Axial Spondyloarthritis Market Key Players

Axial Spondyloarthritis Market Key Players:

The key players operating the Axial Spondyloarthritis Market includes, Amgen, Janssen Biotech, AbbVie, Johnson & Johnson, Novartis Pharmaceuticals Corporation, Pfizer, Eli Lilly and Company, UCB, Kyowa Kirin, Celgene, and Others.

Axial Spondyloarthritis Market Key Issues Addressed

Recent Development:

 The New Launched Product News,

·  In September 2023, the MHRA (Medicines and Healthcare products Regulatory Agency), granted the authorization of marketing bimekizumab (Bimzelx, UCB) for patients who are active with Psoriatric arthritis and for adult patients with active axial spondyloarthritis.

· In October 2022, the U.S. FDA (Food and Drug Administration) approved new ‘Rinvoq’ (upadacitinib), for treating adults with active non-radiographic axial spondyloarthritis with signs of an inflammation.

Axial Spondyloarthritis Market Company Profile

  1. Company Profiles
  • Amgen
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Janssen Biotech
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • AbbVie
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Novartis Pharmaceuticals Corporation
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • UCB
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Kyowa Kirin
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Celgene
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

Axial Spondyloarthritis Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Preview
    • Executive Summary
    • Key Findings—Global Outlook for medical carts Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Type
      • Market Snippet, By Drug Class
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restrains
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Market Segmentation, By Type, Forecast Period up to 10 Years, (US$ Bn)
  • Overview
    • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Ankylosing Spondylitis
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Non-radiographic Axial Spondyloarthritis
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  1. Market Segmentation, By Drug Class, Forecast Period up to 10 Years, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
      • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
      • Segment Trends
    • Glucocorticoids
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
    • Anti-Rheumatic Drugs
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
    • Non-Steroidal Anti-Inflammatory Drugs (NSAID)
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  2. Global Market, By Region, Forecast Period up to 10 Years, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
      • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Year
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
    • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years

 

  • GCC
  • Israel
  • South Africa
  • Rest of Middle East
  1. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis

FAQs

The Axial Spondyloarthritis Market is segmented into Type, Drug Class and Region.

By region, the Axial Spondyloarthritis Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period.

The key players operating the Axial Spondyloarthritis Market includes, Amgen, Janssen Biotech, AbbVie, Johnson & Johnson, Novartis Pharmaceuticals Corporation, Pfizer, Eli Lilly and Company, UCB, Kyowa Kirin, Celgene, and Others.